Efficacy and Safety of Finerenone in Patients Aged 65 Years or Older with Diabetic Kidney Disease: Subgroup Analysis of the FINDKDLATAM Study
Cargando...
Archivos
Fecha
2026
Autores
Rico-Fontalvo, Jorge
Raad Sarabia, María
De La Flor, José C.
Sánchez Polo, Vicente
Benavides Garcia, Jenniffer
Ramos Clason, Enrique
Domínguez, Daniel
Mera Rebutti, Giovanny
Madrid Mancia, Carlos
Tabora López, Rene
Título de la revista
ISSN de la revista
Título del volumen
Editor
MDPI
Resumen
Background and Objectives: Diabetic kidney disease (DKD) is one of the leading causes of
chronic kidney disease (CKD) worldwide. Individuals over 65 years of age with type 2 diabetes
mellitus (T2DM) constitute a growing age group that is frequently underrepresented
in randomized clinical trials. Finerenone has been shown to reduce renal progression and
cardiovascular events in patients with albuminuric DKD. To evaluate the clinical and laboratory
characteristics as well as the therapeutic response and safety profile of finerenone in
patients over 65 years of age with DKD, based on data from the FINDKDLATAM observational
study cohort. Materials and Methods: Subgroup analysis of a real-life, retrospective,
multicenter observational study—the FINDKDLATAM cohort. For the present analysis,
patients aged ≥ 65 years were stratified. Sociodemographic, clinical, paraclinical, and treatment
variables and adverse events were evaluated. The descriptive analysis used medians
with interquartile ranges (IQRs) for continuous variables of non-parametric distribution
and absolute and relative frequencies for categorical variables. The comparison of baseline
parameters and those at six months of follow-up was performed using non-parametric tests,
with statistics. Results: Of the total of 347 patients included in the original study, 157 (45.2%)
were ≥65 years of age. The median age was 72 years. The baseline profile showed a median
glomerular filtration rate (eGFR) of 38.0 mL/min/1.73 m2 (IQR: 30.0–50.75), as well as
elevated albuminuria (ACR 327.0 mg/g; IQR: 186.5–805.5). In addition, the patients had
a high burden of comorbidities. 58.0% of patients received finerenone at a dose of 10 mg
and 42.0% at a dose of 20 mg. After six months of follow-up, a significant reduction in the
median ACR was observed, decreasing from 327.0 mg/g (IQR: 186.5–805.5) to 78.0 mg/g
(IQR: 27.5–143.0), corresponding to a decrease of 76% (p < 0.0001). Regarding safety, hyperkalemia
occurred in 20.3% of patients, although, in all cases, it was mild hyperkalemia
(potassium between 5.1 and 5.5 mEq/L), with no serious episodes or treatment suspensions
attributable to this event. Conclusions: In this cohort of Latin American adults over 65 years
of age with albuminuric DKD, finerenone demonstrated good efficiency given the clinically
significant reduction of albuminuria with stable renal function at six months of treatment,
also demonstrating a safety profile, with a low risk of hyperkalemia.
Descripción
Tabla de contenidos
Palabras clave
Citación
Rico Fontalvo, J., Raad Sarabia, M., De La Flor, J. C., Sánchez Polo, V., Benavides Garcia, J., Ramos Clason, E., Domínguez, D., Mera Rebutti, G., Madrid Mancia, C., Tabora López, R., Rocha Meza, M., Tabora López, D., Zambrano, J. J. M., Lorca Herrera, E., Dina-Batlle, E., Cieza Terrones, M., Proença de Moraes, T., Rodríguez Yánez, T., Osorio, W., ... Arnedo, R. D. (2026). Efficacy and Safety of Finerenone in Patients Aged 65 Years or Older with Diabetic Kidney Disease: Subgroup Analysis of the FINDKDLATAM Study. Medicina, 62(7), 1317. https://doi.org/10.3390/medicina62071317

